Lupin gets USFDA nod for generic equivalent of Zyflo CR Extended-Release Tablets to treat prophylaxis, asthma
"Zileuton Extended-Release Tablets, 600 mg are indicated for the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older, Lupin said in a BSE filing.
New Delhi: Pharma major Lupin Limited (Lupin) announced that it has received approval for its Zileuton Extended-Release Tablets, 600 mg, from the United States Food and Drug Administration (U.S. FDA) for treating prophylaxis and chronic treatment of asthma.
The product is to market a generic equivalent of Zyflo CR Extended-Release Tablets, 600 mg, of Chiesi USA, Inc.
"Zileuton Extended-Release Tablets, 600 mg are indicated for the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older, Lupin said in a BSE filing.
Also Read: Lupin gets USFDA nod for a generic equivalent of Depakote ER Tablets to treat epilepsy in the US
Zileuton Extended-Release Tablets, 600 mg had annual sales of approximately USD 43 million in the U.S. (IQVIA MAT September 2019).
Headquartered in Mumbai, Lupin develops and delivers a range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds a global position in the Anti-TB segment.
Also Read: Lupin gets USFDA nod for a generic version of Levoxyl tablets to treat hypothyroidism
Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd